@article{fc26fdafd4314c4e8af997be88c30c7f,
title = "Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary",
abstract = "This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.",
author = "Garber, {Alan J.} and Abrahamson, {Martin J.} and Barzilay, {Joshua I.} and Lawrence Blonde and Bloomgarden, {Zachary T.} and Bush, {Michael A.} and Samuel Dagogo-Jack and DeFronzo, {Ralph A.} and Daniel Einhorn and Fonseca, {Vivian A.} and Garber, {Jeffrey R.} and Garvey, {W. Timothy} and George Grunberger and Yehuda Handelsman and Hirsch, {Irl B.} and Jellinger, {Paul S.} and McGill, {Janet B.} and Mechanick, {Jeffrey I.} and Rosenblit, {Paul D.} and Umpierrez, {Guillermo E.}",
note = "Funding Information: Dr. Irl B. Hirsch reports that he has received consulting fees from Abbott Diabetes Care, Roche, Bigfoot, and BD. He has also received research grant support from Medtronic. Funding Information: Dr. Vivian A. Fonseca reports that he has received consulting fees from Takeda, Novo Nordisk, Sanofi-Aventis, Asahi, Abbott, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, and Intarcia. He has received speaker fees from Takeda, Novo Nordisk, and Sanofi. He also owns stock in Amgen, Microbiome Technologies, BRAVO4Health, and Insulin Algorithms. Dr. Fonseca has also received research grant support from Asahi, Bayer, and Boehringer Ingelheim. Dr. Jeffrey R. Garber reports that he has received consulting fees from AbbVie. Funding Information: Dr. Janet B. McGill reports that she has received consulting fees from Boehringer Ingelheim, Novo Nordisk, Aegerion, Bayer, Gilead, and Sanofi. She has also received speaker fees from Dexcom, Mannkind, Aegerion, and Janssen. Dr. McGill has received research grant support from Medtronic, Novartis, AstraZeneca/Bristol-Myers-Squibb, the Leona Helmsley Charitable Trust, and Dexcom. Publisher Copyright: Copyright {\textcopyright} 2019 AACE.",
year = "2019",
month = jan,
doi = "10.4158/CS-2018-0535",
language = "English (US)",
volume = "25",
pages = "69--100",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "1",
}